Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation, Discov. Med, vol.13, pp.445-450, 2012. ,
Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route, Pharmaceutical Research, vol.10, issue.6, pp.857-864, 1993. ,
DOI : 10.1023/A:1018909210879
Pharmacology and management of the vitamin K antagonists American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.8, issue.133, pp.160-198, 2008. ,
Oral heparin: status review, Thromb. J, vol.4, pp.1-7, 2006. ,
a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors, Cardiovasc. Drug. Rev, vol.20, pp.37-52, 2002. ,
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa, Journal of Thrombosis and Haemostasis, vol.315, pp.12-19, 2011. ,
DOI : 10.1111/j.1538-7836.2011.04321.x
Oral Delivery of Anticoagulant Doses of Heparin : A Randomized, Double-Blind, Controlled Study in Humans, Circulation, vol.98, issue.16, pp.1610-1615, 1998. ,
DOI : 10.1161/01.CIR.98.16.1610
The role of glutathione in the permeation enhancing effect of thiolated polymers, Pharmaceutical Research, vol.19, issue.5, pp.602-608, 2002. ,
DOI : 10.1023/A:1015345827091
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study, The Lancet, vol.371, issue.9610, pp.387-394, 2008. ,
DOI : 10.1016/S0140-6736(08)60202-0
The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers, Clinical Pharmacokinetics, vol.359, issue.Supplement 2, pp.1-9, 2002. ,
DOI : 10.2165/00003088-200241002-00001
Heparin and low-molecular-weight heparin, Thromb. Haemost, vol.99, pp.897-818, 2008. ,
Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.3, pp.382-387, 2010. ,
DOI : 10.1161/ATVBAHA.110.203117
DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles, J. Thromb. Haemost, vol.6, pp.1542-1549, 2008. ,
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA, pp.269-367, 2006. ,
DOI : 10.1161/CIR.0b013e318214876d
Challenges for the oral delivery of macromolecules, Nature Reviews Drug Discovery, vol.2, issue.4 ,
DOI : 10.1038/nrd1067
Papain: An Effective Permeation Enhancer for Orally Administered Low Molecular Weight Heparin, Pharmaceutical Research, vol.20, issue.6, pp.1001-1006, 2007. ,
DOI : 10.1007/s11095-006-9226-8
New Anticoagulants for Treatment of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.3 ,
DOI : 10.1161/ATVBAHA.108.162677
Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units, Bioorganic & Medicinal Chemistry, vol.12, issue.21, pp.5579-5586, 2004. ,
DOI : 10.1016/j.bmc.2004.08.001
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors, Journal of Medicinal Chemistry, vol.45, issue.9, pp.1757-66, 2002. ,
DOI : 10.1021/jm0109513
Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin, Bioorganic & Medicinal Chemistry, vol.14, issue.1, pp.143-152, 2006. ,
DOI : 10.1016/j.bmc.2005.08.004
Chitosan-based gastrointestinal delivery systems, Journal of Controlled Release, vol.89, issue.2, pp.151-165, 2003. ,
DOI : 10.1016/S0168-3659(03)00126-3
SR 90107A/Org 31540, a Novel Anti-Factor Xa Antithrombotic Agent, Cardiovascular Drug Reviews, vol.3, issue.1, pp.1-26, 1997. ,
DOI : 10.1016/0049-3848(94)90232-1
Current anticoagulant therapy???unmet clinical needs, Thrombosis Research, vol.109, issue.109, 2003. ,
DOI : 10.1016/S0049-3848(03)00250-0
Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004. ,
DOI : 10.1378/chest.126.3_suppl.188S
Microencapsulation of Low Molecular Weight Heparin into Polymeric Particles Designed with Biodegradable and Nonbiodegradable Polycationic Polymers, Drug Delivery, vol.10, issue.1, pp.1-7, 2003. ,
DOI : 10.1080/713840325
Oral bioavailability of a low molecular weight heparin using a polymeric delivery system, Journal of Controlled Release, vol.113, issue.1, pp.38-42, 2006. ,
DOI : 10.1016/j.jconrel.2006.03.020
Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement, Journal of Thrombosis and Haemostasis, vol.1, p.148, 2001. ,
DOI : 10.1111/j.1538-7836.2003.tb05438.x
Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies, International Journal of Pharmaceutics, vol.317, issue.2, pp.114-119, 2006. ,
DOI : 10.1016/j.ijpharm.2006.02.056
Heparin, Pharmacol. Rev, vol.31, pp.100-166, 1980. ,
DOI : 10.1021/ba-1980-0187.ch023
In Vitro and In Vivo Evaluation of Oral Heparin-Loaded Polymeric Nanoparticles in Rabbits, Circulation, vol.105, issue.2, pp.230-235, 2002. ,
DOI : 10.1161/hc0202.101988
The anticoagulant activation of antithrombin by heparin, Proc. Natl. Acad. Sci. USA, pp.14683-14688, 1997. ,
DOI : 10.1073/pnas.94.26.14683
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors, American Journal of Hematology, vol.171, issue.Suppl 1, pp.141-146, 2012. ,
DOI : 10.1002/ajh.23202
Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil ,
Edoxaban for prevention of venous thromboembolism after major orthopedic surgery, Orthopedic Research and Reviews, vol.4, pp.53-64, 2012. ,
DOI : 10.2147/ORR.S24583
Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates, Journal of Controlled Release, vol.105, issue.1-2, pp.32-42, 2005. ,
DOI : 10.1016/j.jconrel.2005.03.018
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.43, issue.suppl A, pp.743-753, 2010. ,
DOI : 10.1177/0091270009351883
Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012. ,
DOI : 10.1002/med.20217
Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation, International Journal of Pharmaceutics, vol.422, issue.1-2, pp.179-184, 2012. ,
DOI : 10.1016/j.ijpharm.2011.10.048
Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules, Pharmaceutical Research, vol.47, issue.6, pp.1243-1250, 2006. ,
DOI : 10.1007/s11095-006-0022-2
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor, Journal of Thrombosis and Haemostasis, vol.10, issue.3, pp.514-521, 2005. ,
DOI : 10.1016/0049-3848(89)90210-7
Factor Xa inhibitors. New anticoagulants for secondary haemostasis, Hämostaseologie, vol.29, pp.260-267, 2009. ,
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor, Nature Reviews Drug Discovery, vol.110, issue.1, pp.61-75, 2011. ,
DOI : 10.1038/nrd3185
H??parines de synth??se., m??decine/sciences, vol.15, issue.11, pp.1325-1328, 1999. ,
DOI : 10.4267/10608/1270
1976???1983, a critical period in the history of heparin: the discoveryof the antithrombin binding site, Biochimie, vol.85, issue.1-2, pp.83-89, 2003. ,
DOI : 10.1016/S0300-9084(03)00078-6
New anticoagulants, Journal of Thrombosis and Haemostasis, vol.119, issue.8, pp.1843-1853, 2005. ,
DOI : 10.1111/j.1538-7836.2004.00890.x
URL : https://hal.archives-ouvertes.fr/hal-00935589
Update on heparin: what do we need to know?, Journal of Thrombosis and Thrombolysis, vol.86, issue.2, pp.199-207, 2010. ,
DOI : 10.1007/s11239-009-0411-6
New Antithrombotic Drugs, Chest, vol.141, issue.2, pp.120-151, 2012. ,
DOI : 10.1378/chest.11-2294
In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, Thrombosis and Haemostasis, vol.98, pp.155-162, 2007. ,
DOI : 10.1160/TH07-03-0183
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor, Journal of Thrombosis and Thrombolysis, vol.38, issue.1, pp.478-492, 2011. ,
DOI : 10.1007/s11239-011-0551-3
Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber, Ad. Drug Del. Rev, 2012. ,
Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents - The Selective Factor Xa Inhibitors, Cardiovascular Drug Reviews, vol.32, issue.Suppl 1, pp.37-52, 2002. ,
DOI : 10.1111/j.1527-3466.2002.tb00081.x
Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004. ,
DOI : 10.1378/chest.126.3_suppl.188S
Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux), Thrombosis Research, vol.109, issue.1, pp.1-11, 2003. ,
DOI : 10.1016/S0049-3848(03)00030-6
A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types, Journal of Controlled Release, vol.124, issue.1-2, pp.20-27, 2007. ,
DOI : 10.1016/j.jconrel.2007.08.018
Squalene and its potential clinical uses, Alt. Med. Rev, vol.4, pp.29-36, 1999. ,
The growing impact of click chemistry on drug discovery, Drug Discovery Today, vol.8, issue.24, pp.1128-1137, 2003. ,
DOI : 10.1016/S1359-6446(03)02933-7
New amphiphilic derivatives of heparin, grafted to bile acids, useful as vectors for oral delivery, 2003. ,
The selective oxidation of the terminal double bonds in squalene, Tetrahedron Letters, vol.3, issue.3, pp.121-124, 1962. ,
DOI : 10.1016/S0040-4039(00)71112-9
Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, vol.41, pp.489-497, 2010. ,
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011. ,
Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011. ,
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int. J. Nanomed, vol.6, pp.2941-2951, 2011. ,
Design, synthesis, and micellar properties of bile acid dimers and oligomers linked with a 1,2,3-triazole ring, Tetrahedron, vol.63, issue.52, pp.12927-12934, 2007. ,
DOI : 10.1016/j.tet.2007.10.042
Synthesis and Electronic Factors in Thermal Cyclodimerization of Functionalized Aromatic Trifluorovinyl Ethers, Journal of the American Chemical Society, vol.128, issue.21, pp.7055-7064, 2006. ,
DOI : 10.1021/ja0600227
A Chemoenzymatic Approach to Glycopeptide Antibiotics, Journal of the American Chemical Society, vol.126, issue.43, pp.13998-14003, 2004. ,
DOI : 10.1021/ja045147v
The anticoagulant activation of antithrombin by heparin, Proc. Natl. Acad. Sci. USA, pp.14683-14688, 1997. ,
DOI : 10.1073/pnas.94.26.14683
Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent, Circulation, vol.104, issue.25, pp.3116-3120, 2001. ,
DOI : 10.1161/hc5001.100627
Oral delivery of new heparin derivatives in rats, Pharmaceutical Research, vol.17, issue.10, pp.1259-1264, 2000. ,
DOI : 10.1023/A:1026474919869
Development of idraparinux and idrabioparinux for anticoagulant therapy ,
SR 90107/org 31540, a novel anti-Factor Xa antithrombotic agent, Cardiov. Drug Rev, vol.15, pp.1-26, 1997. ,
Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, vol.41, pp.489-497, 2010. ,
The quest for non-invasive delivery of bioactive macromolecules: A focus on heparins, Journal of Controlled Release, vol.113, issue.2, pp.91-101, 2006. ,
DOI : 10.1016/j.jconrel.2006.04.008
Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents - The Selective Factor Xa Inhibitors, Cardiovascular Drug Reviews, vol.32, issue.Suppl 1, pp.37-52, 2002. ,
DOI : 10.1111/j.1527-3466.2002.tb00081.x
Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011. ,
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011. ,
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int. J. Pharm, vol.422, pp.179-184, 2012. ,
Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2012. ,
DOI : 10.1016/j.jconrel.2011.07.038
Squalene and its potential clinical uses, Alter. Med Rev, vol.4, pp.29-36, 1999. ,
Squalenoyl nanomedicines as potential therapeutics, Nano Lett, vol.6, pp.2544-2548, 2006. ,
Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012. ,
DOI : 10.1002/med.20217
Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin, Bioorganic & Medicinal Chemistry, vol.14, issue.1 ,
DOI : 10.1016/j.bmc.2005.08.004
Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin, European Journal of Pharmaceutics and Biopharmaceutics, vol.69, issue.2, pp.417-425, 2008. ,
DOI : 10.1016/j.ejpb.2008.01.016
Bioadhesion and oral absorption of enoxaparin nanocomplexes, International Journal of Pharmaceutics, vol.386, issue.1-2, pp.275-281, 2010. ,
DOI : 10.1016/j.ijpharm.2009.11.025
Liphophilic complexation of heparin based on bile acid for oral delivery, Journal of Controlled Release, vol.123, issue.1, pp.39-45, 2007. ,
DOI : 10.1016/j.jconrel.2007.07.013
A novel formulation for controlled release of heparin???DOCA conjugate dispersed as nanoparticles in polyurethane film, Biomaterials, vol.22, issue.3, pp.281-289, 2001. ,
DOI : 10.1016/S0142-9612(00)00194-0
Trisnorsqualene alcohol, a potent inhibitor of vertebrate squalene epoxidase, Journal of the American Chemical Society, vol.111, issue.4, pp.1508-1510, 1989. ,
DOI : 10.1021/ja00186a062
Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation, International Journal of Pharmaceutics, vol.344, issue.1-2, pp.33-43, 2007. ,
DOI : 10.1016/j.ijpharm.2007.05.054
URL : https://hal.archives-ouvertes.fr/hal-00180715
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.133, pp.844-86, 2008. ,
New Anticoagulants for Treatment of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.3 ,
DOI : 10.1161/ATVBAHA.108.162677
Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.3, pp.382-387, 2010. ,
DOI : 10.1161/ATVBAHA.110.203117
Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, vol.123, pp.269-367, 2006. ,
Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study, Circulation, vol.110, pp.1042-1046, 2004. ,
Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004. ,
DOI : 10.1378/chest.126.3_suppl.188S
Pharmacology and management of the vitamin K antagonists American College of Chest Physicians Evidence- Based Clinical Practice Guidelines, Chest, vol.8, issue.133, pp.160-198, 2008. ,
Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents - The Selective Factor Xa Inhibitors, Cardiovascular Drug Reviews, vol.32, issue.Suppl 1, pp.37-52, 2006. ,
DOI : 10.1111/j.1527-3466.2002.tb00081.x
New anticoagulants, Journal of Thrombosis and Haemostasis, vol.119, issue.8, pp.1843-1853, 2005. ,
DOI : 10.1111/j.1538-7836.2004.00890.x
URL : https://hal.archives-ouvertes.fr/hal-00935589
SR 90107A/Org 31540, a Novel Anti-Factor Xa Antithrombotic Agent, Cardiovascular Drug Reviews, vol.3, issue.1, pp.1-26, 1997. ,
DOI : 10.1016/0049-3848(94)90232-1
Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux), Thrombosis Research, vol.109, issue.1, pp.1-11, 2011. ,
DOI : 10.1016/S0049-3848(03)00030-6
Heparin, Pharmacol Rev, vol.31, pp.100-66, 1980. ,
DOI : 10.1021/ba-1980-0187.ch023
Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature, Thrombosis Research, vol.129, issue.3, pp.392-400, 2012. ,
DOI : 10.1016/j.thromres.2011.12.014
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa, Journal of Thrombosis and Haemostasis, vol.315, issue.9, pp.12-19, 2011. ,
DOI : 10.1111/j.1538-7836.2011.04321.x
Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent, Circulation, vol.104, issue.25, pp.3116-3136, 2001. ,
DOI : 10.1161/hc5001.100627
Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant, Journal of Controlled Release, vol.120, issue.1-2, pp.4-10, 2007. ,
DOI : 10.1016/j.jconrel.2007.03.008
Papain: An Effective Permeation Enhancer for Orally Administered Low Molecular Weight Heparin, Pharmaceutical Research, vol.20, issue.6, pp.1001-1006, 2007. ,
DOI : 10.1007/s11095-006-9226-8
Development and in vivo evaluation of an oral delivery system for low molecular ,
Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: Pharmacological considerations, Pharmaceutical Research, vol.14, issue.12, pp.1830-1834, 1997. ,
DOI : 10.1023/A:1012160703533
Oral Delivery of Anticoagulant Doses of Heparin : A Randomized, Double-Blind, Controlled Study in Humans, Circulation, vol.98, issue.16, pp.1610-1615, 1998. ,
DOI : 10.1161/01.CIR.98.16.1610
Acylated non-??-amino acids as novel agents for the oral delivery of heparin sodium, USP, Journal of Controlled Release, vol.50, issue.1-3, pp.41-49, 1998. ,
DOI : 10.1016/S0168-3659(97)00101-6
Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin, European Journal of Pharmaceutics and Biopharmaceutics, vol.69, issue.2, pp.417-425, 2008. ,
DOI : 10.1016/j.ejpb.2008.01.016
The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin, Biomaterials, vol.30, issue.34, pp.6629-6637, 2009. ,
DOI : 10.1016/j.biomaterials.2009.08.030
Bioadhesion and oral absorption of enoxaparin nanocomplexes, International Journal of Pharmaceutics, vol.386, issue.1-2, pp.275-281, 2010. ,
DOI : 10.1016/j.ijpharm.2009.11.025
Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation, International Journal of Pharmaceutics, vol.422, issue.1-2, pp.179-184, 2012. ,
DOI : 10.1016/j.ijpharm.2011.10.048
Microencapsulation of Low Molecular Weight Heparin into Polymeric Particles Designed with Biodegradable and Nonbiodegradable Polycationic Polymers, Drug Delivery, vol.10, issue.1, pp.1-7, 2003. ,
DOI : 10.1080/713840325
Oral bioavailability of a low molecular weight heparin using a polymeric delivery system, Journal of Controlled Release, vol.113, issue.1, pp.38-42, 2006. ,
DOI : 10.1016/j.jconrel.2006.03.020
Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates, Journal of Controlled Release, vol.105, issue.1-2, pp.32-42, 2005. ,
DOI : 10.1016/j.jconrel.2005.03.018
Development and in vivo bioavailability study of an oral fondaparinux delivery system, European Journal of Pharmaceutical Sciences, vol.41, issue.3-4, pp.489-497, 2010. ,
DOI : 10.1016/j.ejps.2010.08.001
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int J Pharm, vol.422, pp.179-184, 2012. ,
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011. ,
Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011. ,
Squalene and its potential clinical uses, Altern Med Rev, vol.4, pp.29-36, 1999. ,
Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2011. ,
DOI : 10.1016/j.jconrel.2011.07.038
Squalenoyl Nanomedicines as Potential Therapeutics, Squalenoyl nanomedicines as potential therapeutics, pp.2544-2548, 2006. ,
DOI : 10.1021/nl061942q
Oral absorption and tissue distribution of a new squalenoyl anticancer nanomedicine, Journal of Nanoparticle Research, vol.18, issue.5, pp.887-891, 2008. ,
DOI : 10.1007/s11051-007-9322-7
Freeze-drying of squalenoylated nucleoside analogue nanoparticles, International Journal of Pharmaceutics, vol.381, issue.2, pp.140-145, 2009. ,
DOI : 10.1016/j.ijpharm.2009.04.002
Emerging anticoagulants for the treatment of venous thromboembolism, Thrombosis and Haemostasis, vol.96, pp.274-84, 2006. ,
DOI : 10.1160/TH06-05-0234
Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012. ,
DOI : 10.1002/med.20217
Freeze-drying of nanoparticles: Formulation, process and storage considerations???, Advanced Drug Delivery Reviews, vol.58, issue.15, pp.1688-713, 2006. ,
DOI : 10.1016/j.addr.2006.09.017
Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery, International Journal of Pharmaceutics, vol.305, issue.1-2, pp.22-30, 2005. ,
DOI : 10.1016/j.ijpharm.2005.08.025
a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors, Cardiov. Drug. Rev, vol.20, pp.37-52, 2002. ,
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.133, pp.844-86, 2008. ,
Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux), Thrombosis Research, vol.109, issue.1, pp.1-11, 2003. ,
DOI : 10.1016/S0049-3848(03)00030-6
Pharmacology and management of the vitamin K antagonists American College of Chest Physicians Evidence- Based Clinical Practice Guidelines, Chest, vol.8, issue.133, pp.160-198, 2008. ,
Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature, Thrombosis Research, vol.129, issue.3, pp.392-400, 2012. ,
DOI : 10.1016/j.thromres.2011.12.014
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update, Journal of Thrombosis and Thrombolysis, vol.29, issue.2, pp.326-343, 2011. ,
DOI : 10.1007/s11239-011-0561-1
New direct oral anticoagulants ??? current therapeutic options and treatment recommendations for bleeding complications, Thrombosis and Haemostasis, vol.108, issue.4, pp.1-7, 2012. ,
DOI : 10.1160/TH12-05-0319
Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012. ,
DOI : 10.1002/med.20217
Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, vol.41, pp.489-497, 2010. ,
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int. J. Nanomed, vol.6, pp.2941-2951, 2011. ,
Novel self assembling nanoparticles for the oral administration of fondaparinux : synthesis, characterization and in vivo evaluation ,
Squalene and its potential clinical uses, Alt. Med. Rev, vol.4, pp.29-36, 1999. ,
Development and in vivo evaluation of novel squalenoyl-fondaparinux nanoparticles as efficient delivery for oral administration of anticoagulant agents ,
An in Vitro Study with an Ussing Chamber Showing That Unfractionated Heparin Crosses Rat Gastric Mucosa, Journal of Pharmacology and Experimental Therapeutics, vol.322, issue.1, pp.299-305, 2007. ,
DOI : 10.1124/jpet.106.116939
Low Molecular Weight Heparins Cross Rat Gastric Mucosa Mounted in an Ussing Chamber, International Journal of Pharmacology, vol.4, issue.6, pp.431-442, 2008. ,
DOI : 10.3923/ijp.2008.431.442
Movement of Heparins Across Rat Gastric Mucosa is Dependent on Molecular Weight and pH, Pharmaceutical Research, vol.234, issue.6, pp.189-195, 2009. ,
DOI : 10.1007/s11095-008-9751-8
A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method, European Journal of Pharmaceutics and Biopharmaceutics, vol.58, issue.3, pp.659-665, 2004. ,
DOI : 10.1016/j.ejpb.2004.03.029
Hypotonicity induced K+ and anion conductive pathways activation in eel intestinal epithelium, Journal of Experimental Biology, vol.208, issue.4, pp.749-760, 2005. ,
DOI : 10.1242/jeb.01440
Bidirectional Small-Intestinal Permeability in the Rat to Some Common Marker Molecules in vitro, Scandinavian Journal of Gastroenterology, vol.242, issue.8, pp.703-709, 1994. ,
DOI : 10.3109/00365529409092497
Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant, Journal of Controlled Release, vol.120, issue.1-2, pp.4-10, 2007. ,
DOI : 10.1016/j.jconrel.2007.03.008
Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv. Drug Del. Rev. In press, 2012. ,
Combined hydroxypropyl-?-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur, J. Pharm. Sc, vol.38, pp.405-413, 2009. ,
Transcellular uptake mechanisms of the intestinal epithelial barrier Part one, Pharmaceutical Science & Technology Today, vol.2, issue.4, pp.144-151, 1999. ,
DOI : 10.1016/S1461-5347(99)00142-X
Permeability of human jejunal segments to gonyautoxins measured by the Ussing chamber technique, Toxicon, vol.44, issue.5, pp.521-528, 2004. ,
DOI : 10.1016/j.toxicon.2004.07.003
Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo, European Journal of Pharmaceutical Sciences, vol.25, issue.4-5, pp.445-453, 2005. ,
DOI : 10.1016/j.ejps.2005.04.003
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview, The Oncologist, vol.7, issue.6, pp.516-530, 2002. ,
DOI : 10.1634/theoncologist.7-6-516
Freeze-drying of nanoparticles: formulation, process and storage considerations, Adv. Drug Deliv. Rev, vol.58, pp.1688-713, 2006. ,
Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues, Adv. Funct. Mater, vol.18, pp.3715-3725, 2008. ,
Freeze-drying of squalenoylated nucleoside analogue nanoparticles, International Journal of Pharmaceutics, vol.381, issue.2, pp.140-145, 2009. ,
DOI : 10.1016/j.ijpharm.2009.04.002
The effect of verapamil on the pharmacokinetics of paclitaxel in rats, European Journal of Pharmaceutical Sciences, vol.24, issue.1 ,
DOI : 10.1016/j.ejps.2004.10.002
Squalenoyl nanomedicines as potential therapeutics, Nano Lett, vol.6, pp.2544-2548, 2006. ,
Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2012. ,
DOI : 10.1016/j.jconrel.2011.07.038
Novel Nanoassemblies Composed of Squalenoyl???Paclitaxel Derivatives: Synthesis, Characterization, and Biological Evaluation, Bioconjugate Chemistry, vol.21, issue.7 ,
DOI : 10.1021/bc100154g
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview, The Oncologist, vol.7, issue.6, pp.516-530, 2002. ,
DOI : 10.1634/theoncologist.7-6-516
Oral delivery of new heparin derivatives in rats, Pharmaceutical Research, vol.17, issue.10, pp.1259-1264, 2000. ,
DOI : 10.1023/A:1026474919869
Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent, Circulation, vol.104, issue.25, pp.3116-3120, 2001. ,
DOI : 10.1161/hc5001.100627
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011. ,
P-glycoprotein and pharmacokinetics, Anticancer Res, vol.15, pp.331-336, 1995. ,
Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011. ,
Low Molecular Weight Heparins Cross Rat Gastric Mucosa Mounted in an Ussing Chamber, International Journal of Pharmacology, vol.4, issue.6, pp.431-442, 2008. ,
DOI : 10.3923/ijp.2008.431.442
Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules, Pharmaceutical Research, vol.47, issue.6, pp.1243-1250, 2006. ,
DOI : 10.1007/s11095-006-0022-2
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. USA, pp.2031-2035, 1997. ,
DOI : 10.1073/pnas.94.5.2031
Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, p.41, 2010. ,